The stock of aTyr Pharma Inc (NASDAQ:LIFE) is a huge mover today! About 243,069 shares traded hands or 87.88% up from the average. aTyr Pharma Inc (NASDAQ:LIFE) has declined 36.77% since March 3, 2016 and is downtrending. It has underperformed by 45.11% the S&P500.
The move comes after 9 months negative chart setup for the $71.82 million company. It was reported on Oct, 6 by Barchart.com. We have $2.61 PT which if reached, will make NASDAQ:LIFE worth $9.34 million less.
Analysts await aTyr Pharma Inc (NASDAQ:LIFE) to report earnings on November, 8. They expect $-0.66 earnings per share, down 37.50% or $0.18 from last year’s $-0.48 per share. After $-0.65 actual earnings per share reported by aTyr Pharma Inc for the previous quarter, Wall Street now forecasts 1.54% negative EPS growth.
aTyr Pharma Inc (NASDAQ:LIFE) Ratings Coverage
Out of 4 analysts covering Life Technologies Corp (NASDAQ:LIFE), 1 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 25% are positive. Life Technologies Corp has been the topic of 6 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating by William Blair given on Thursday, March 31. As per Wednesday, December 16, the company rating was initiated by Citigroup. The stock has “Overweight” rating given by JP Morgan on Thursday, August 11. The company was maintained on Tuesday, August 16 by Citigroup. The stock has “Sell” rating given by Zacks on Thursday, September 17. The stock of aTyr Pharma Inc (NASDAQ:LIFE) earned “Hold” rating by Zacks on Tuesday, August 25.
According to Zacks Investment Research, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.”
More notable recent aTyr Pharma Inc (NASDAQ:LIFE) news were published by: Streetinsider.com which released: “aTyr Pharma (LIFE) Announces Additional Data on Resolaris Phase 1b/2 …” on October 06, 2016, also Prnewswire.com with their article: “aTyr Pharma Appoints Sanuj Ravindran, M.D., as Chief Business Officer” published on January 06, 2016, Prnewswire.com published: “aTyr Pharma Announces Second Quarter 2016 Operating Results” on August 10, 2016. More interesting news about aTyr Pharma Inc (NASDAQ:LIFE) were released by: Quotes.Wsj.com and their article: “News aTyr Pharma Inc.LIFE” published on February 12, 2011 as well as Prnewswire.com‘s news article titled: “aTyr Pharma Doses First Patient In Long-Term Safety Extension Study Of …” with publication date: September 10, 2015.
LIFE Company Profile
aTyr Pharma, Inc., incorporated on October 8, 2005, is a clinical-stage biotherapeutics company. The Firm is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Firm focuses on the development of Physiocrine therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.